 It may help decrease a change of response to Parkinson's medications.In the EU it is indicated for the treatment of adults with Parkinson's disease and end-of-dose motor fluctuations not stabilized on levodopa/dopa decarboxylase (DDC) inhibitor treatment.Sometimes a wearing off effect may occur at the end of the dosing interval, where a patient may feel Parkinson's symptoms.